Vancouver, British Columbia (Newsfile Corp. - June 3, 2021) - Cabral Gold Inc. (TSXV: CBR) (OTC PINK: CBGZF) ("Cabral" or the "Company") is pleased to advise that following the recent identification
Cabral Gold Inc.
(“Cabral” or the “
Company“) is pleased to provide assay results from several recently completed diamond drill holes at the MG gold deposit, and several reconnaissance RC holes at the JM target within the Cuiú Cuiú gold
district in northern Brazil.
Try refreshing your browser. Cabral Gold Drills 60m at 3.5 g/t gold including 2.6m at 64.6 g/t gold in Oxide Blanket at the MG Gold Deposit, Cuiú Cuiú District, Brazil Back to video
Highlights are as follows:
DDH-214 drilled at MG returned
60m @ 3.5 g/t gold including 2.6m @ 64.6 g/t gold from surface, suggesting that parts of the recently identified mineralized blanket at MG are significantly thicker and higher grade than initially envisaged. This intercept represents the thickest and highest-grade mineralized intercept to date from the oxide gold blanket which overlies the underlying and sub-vertically dipping MG gold deposit
NA Proactive news snapshot: Zynerba Pharmaceuticals, Nerds On Site, Marvel Discovery, Water Tower Research UPDATE …
A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters at the Society of Biological Psychiatry (SOBP) 2021 Virtual Meeting. The first poster is titled, “Cannabidiol in Fragile X Syndrome (FXS): Proposed Mechanism of Action (MOA) Translates Into Meaningful Clinical Benefits [CONNECT-FX (ZYN2-CL-016)]. The second poster is titled, “A Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Fragile X Syndrome [CONNECT-FX (ZYN2-CL-016)].”
NA Proactive news snapshot: Zynerba Pharmaceuticals, Nerds On Site, Marvel Discovery, Water Tower Research UPDATE …
A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters at the Society of Biological Psychiatry (SOBP) 2021 Virtual Meeting. The first poster is titled, “Cannabidiol in Fragile X Syndrome (FXS): Proposed Mechanism of Action (MOA) Translates Into Meaningful Clinical Benefits [CONNECT-FX (ZYN2-CL-016)]. The second poster is titled, “A Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Fragile X Syndrome [CONNECT-FX (ZYN2-CL-016)].”